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Background: It has been recently reported that local injection of autologous blood in tennis elbow offers a
significant benefit by virtue of various growth factors contained therein. The objective of our study was assessment
of efficacy of autologous blood injection versus local corticosteroid injection in the treatment of tennis elbow.
Methods and trial design: A single blinded, prospective parallel group trial was undertaken. 50 consecutive
patients of untreated lateral epicondylitis were enrolled. Randomisation was done on alternate basis and two
groups were constituted, first one receiving steroid injection and second one injection of autologous blood. Both
groups were evaluated at 2 and 6 weeks for pain relief and stage of disease.
Results: Baseline evaluation showed no difference between the two groups (chi square test, P > 0.05). Between
group analysis at 2 weeks showed no difference in pain relief and Nirschl stage (unpaired t test, P > 0.05).
Evaluation at 6 weeks demonstrated a significant decrease in pain levels and stage of disease in blood group
(unpaired t test, p < 0.05).
Conclusions: Autologous blood injection was more effective than steroid injection in the short term follow up in
tennis elbow.
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Lateral tendinosis of the elbow popularly known as ten-
nis elbow refers to a degenerative process in the com-
mon origin of the extensor group of muscles of the
forearm. The disorder arising as a result of repetitive
movements of the involved muscles is a common cause
of elbow pain particularly in the working age group. The
disease imparts significant disability to those affected in
terms of the quantity and quality of work done. Tennis
elbow may cause significant weakness of grip strength
particularly with the elbow in extension affecting a vast
majority of daily life activities [1].
Although the diagnosis of lateral tendinosis is quite
straight forward, there has been no consensus on the opti-
mal management strategy [2]. Different treatment ap-
proaches exist with numerous and sometimes contradictory* Correspondence: nipun17online@gmail.com
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reproduction in any medium, provided the oroptions with different mechanisms of action. With reports
of tennis elbow being a degenerative process rather than an
inflammatory one [3], the entire plethora of modalities
aimed at arresting the inflammatory cascade seem ineffec-
tive. Nevertheless local injection of steroid has been proven
to impart a consistent and predictable good short term pain
relief [4]. Delivery of autologous blood derived growth fac-
tors to the site of disease has also been shown to signifi-
cantly help the healing process in tennis elbow [5]. These
growth factors can be delivered by an injection of whole
blood or platelet concentrate. However scientific clinical evi-
dence supporting incorporation of such modalities into rou-
tine clinical practice is scanty at present [6,7].
This trial was thus undertaken in patients of tennis
elbow, to compare the short term benefits of a single in-
jection of steroid and autologous blood in terms of pain
relief and downstaging of the disease.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Trial design
This study was single blinded, parallel group trial involv-
ing untreated patients of lateral tendinosis of the elbow
joint reporting to a tertiary level hospital from August
2009 to August 2010 with an equal allocation ratio (1:1)
to both groups. The study was approved by Ethics Com-
mittee of SMS Medical College and attached Hospitals
with approval number 32167. The trial was registered
with the institutional review board only in the absence of
a nationwide trial registry in India at the time the study
was instituted.
Participants
Eligible participants were all the patients who were pre-
viously untreated and had no other identifiable cause of
lateral elbow pain. A detailed clinical history was taken
in all patients particularly regarding the degree of pain
and the activity restrictions. Standard anteroposterior
and lateral views of the elbow were obtained in all cases
to rule out other causes of lateral elbow pain like
radiocapitellar arthritis. Those reporting with the typical
symptoms of tennis elbow and having no radiographic
cause of pain were included in our study.
All the patients gave informed consent to participate
in the study and were given the right to withdraw from
the study at any time without any reprisal. 50 cases were
selected to participate in our study.
Interventions
Two groups were formed with one group receiving local
steroid injection and the other one local injection of au-
tologous blood. The cases were allotted to the groups on
alternate basis. In Group I, 40 mg of methyl prednisol-
one acetate was used along with 1ml of 2% lignocaine
solution. In Group II, 2 ml of venous blood was drawn
from the ipsilateral or the contralateral upper limb and
was injected after mixing with 1 ml of 2% lignocaine so-
lution. The injection was administered in the outpatient
department itself observing all aseptic precautions by
same author (YG) in all the cases. The needle was intro-
duced just proximal to the lateral epicondyle and the
contents were injected on the undersurface of the exten-
sor carpi radialis group of muscles. Patients were advised
to restrain from activities involving repetitive move-
ments of the wrist and elbow during initial 3 weeks after
injection. Gentle passive stretching exercises of the ex-
tensor group of muscles was started as soon as the pain
permitted.
Outcome
The evaluation of the patients was carried out by the de-
gree of the pain and the amount of disability in the pre
injection phase, and at subsequent outpatient visits at 2and 6 weeks. The degree of pain was assessed by
employing the Visual Analogue scale (VAS) and the de-
gree of disability was evaluated by Nirschl staging [8].
Outcome assessment was conducted by an independent
observer (RL) blinded to the type of intervention re-
ceived by an individual.
Sample size
The minimum sample size required for this study was
calculated on the basis of VAS pain intensity measure-
ments. A significance criterion of 0.05 and power of 90%
was chosen. Minimum expected difference between the
two groups was chosen to be 1.5 on the pain scale. The
minimum sample size came out to be 21 for each group
based on the formula described for comparative research
studies by Eng [9]. Standard deviation was taken to be
1.5 based on the values provided by Edwards et al. Based
on an anticipated dropout rate of 10%, 50 patients were
enrolled with 25 in each group. A post hoc analysis re-
vealed that the study achieved a power of 84.7%.
Statistical analysis
Chi square test was employed in comparison of baseline
pattern of two groups. Paired t test was used for serial
analysis in both groups and unpaired t test for compari-
son between the two groups. Statistical analysis was done
using SPSS v.19 software (SPSS Inc., Chicago, Illinois).
Results
A total of 50 patients with untreated lateral elbow
tendinopathy of varying duration were included in this
study during the time period from August 2009 to August
2010. The two groups comprised of 25 patients each, quasi
randomized by alternate allocation. All the patients were
administered treatment and analyzed as per treatment
protocol.
Baseline characteristics
A comparison of the baseline demographic and clinical
data in both the groups was done (Table 1). Upon appli-
cation of statistical tests, the difference between the two
groups was found out to be non significant.
Group I
The mean VAS scores in the pre injection phase was 6.20 ±
1.61. The pain decreased to a mean VAS of 3.52 ± 1.19
after 2 weeks of steroid injection. The mean VAS at 6
weeks of follow up was 2.28 ± 1.28. Similarly the mean
value of Nirschl stage in Group 1 before administration of
steroid was 4.84 ± 0.94. The mean Nirschl stage at 2 week
and 6 week follow up was 3.20 ± 0.91 and 2.40 ± 1.15 re-
spectively. The mean decrease observed in the VAS scores
and Nirschl stage at 2 week and 6 week follow up after







Age#(in years) 37.32 (7.52) 39.04 (6.67) 0.3965
(NS)
Sex*(males/females) 17/8 14/11 0.2268
(NS)
Laterality* (Right/Left) 21/4 23/2 0.1404
(NS)
Mean duration of symptoms#
(in weeks)
4.4 (2.38) 4.48 (1.82) 0.8944
(NS)
Mean VAS Score# 6.2 (1.61) 5.88 (1.83) 0.5147
(NS)
Mean Nirschl stage # 4.84 (0.94) 4.52 (1.23) 0.3065
(NS)
*chi square test, #unpaired t test, NS – not significant.
Table 3 Evaluation of outcome in blood group








Statistical significance* P < 0.0001 (HS) P < 0.0001 (HS)




Statistical significance* P < 0.0001 (HS) P < 0.0001 (HS)
*Paired t test, HS - highly significant.
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(p<0.0001) (Table 2).
Group II
The baseline pain according to mean VAS score was
5.88 ± 1.83. The mean VAS score observed at 2 week
and 6 week review came out to be 4.24 ± 1.64 and 1.52
± 1.26 respectively. After application of paired t test, the
p value for the fall in mean VAS score came out to be
less than 0.0001 suggesting a extremely significant de-
crease in pain levels at both 2 and 6 week follow up. The
mean Nirschl stage before blood injection was 4.52 ±
1.23 which subsequent to intervention decreased to 3.48
± 1.39 at 2 weeks of follow up. The stage further de-
creased to a mean of 1.40 ± 1.22 at 6 week review. The
change in Nirschl stage at both 2 and 6 weeks of review
in Group 2 came out to be highly significant (p<0.0001)
on paired t test (Table 3).
The above observations reveal that both steroid and
blood injections independently gave a significant pain re-
lief and significantly downstaged the disease in a short
term follow up.
Between group analysis
After an initial analysis of the two groups separately,
comparisons were drawn. The pre injection mean VASTable 2 Ealuation of outcome in steroid group

















Statistical significance* P < 0.0001 (HS) P < 0.0001 (HS)
*Paired t test, HS - highly significant.score and the mean value of the Nirschl stage was simi-
lar in both groups. The mean VAS scores in both the
groups were plotted on a line diagram (Figure 1).
Clinically it was found that pain relief at 2 weeks was
more in steroid group while it was more at 6 weeks of
review in blood group. However, statistical comparison
between the two groups revealed that the mean VAS
values at 2 weeks in both groups were similar while at 6
weeks it was significantly lower in group II (Table 4).
Similar to the above comparison, Nirschl stage was
compared at 2 and 6 weeks post injection in both the
groups (Figure 2). At 2 weeks, although the downstaging
in group I was clinically better, statistical analysis yielded
no significant result between the two groups. The com-
parison of mean VAS and mean Nirschl stage at 6 weeks
of review came out to be highly significant indicating su-
periority of blood over steroid (Table 5).
The relief of pain from pre injection phase to 6 weeks
review was graded as fair (0–3), good (4–6), excellent
(≥7). The relief was excellent in 3 (12%) and 1 (4%) pa-
tients in blood and steroid groups respectively. Good
and fair results were obtained in 14 (56%) and in 8
(32%) patients in blood group and 12 (48%) and 12
(48%) patients correspondingly.
Discussion
Lateral elbow epicondylopathy remains one of the most
perplexing disorders of the musculoskeletal system. It
was first described by Runge [10] in 1873. The designa-
tion lateral epicondylitis is a misnomer since it has been
proved that it is primarily a disorder related to degener-
ation in the tendon of common extensor origin (mostly
extensor carpi radialis brevis) rather than inflammatory
process as was thought to be earlier [3]. Maffuli et al.
[11] recognised that tendinopathy is a clinical diagnosis
while tendinitis or tendinosis terms should be reserved
only after histopathological examination has been car-
ried out. A cadaveric study by Bales et al. [12] showed
two zones of hypovascularity in the region of lateral epi-
condyle, one between the lateral epicondyle and the
supracondylar ridge and the other on the deep surface of
common extensor tendon 2–3 cms distal to lateral epi-
condyle. This is probably the area where the degenerative
Figure 1 Line plot of the mean VAS scores in the pre injection phase, at 2 week follow up and at 6 weeks of review in both
the groups.
Table 4 Between-group comparison of Mean VAS scores
at baseline and after 2 and 6 weeks of treatment
Pre injection At 2 weeks At 6 weeks
Group I 6.20 (1.61) 3.52 (1.19) 2.28 (1.28)
Group II 5.88 (1.83) 4.24 (1.64) 1.52 (1.26)
P value# 0.5147 0.0820 0.0396
Significance NS NS Significant
#unpaired t test, NS – not significant.
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tendinitis arises in a hypovascular zone just proximal to
tendon insertion). The term Tennis elbow is not too apt
since this disorder is commoner in occupations which in-
volve repetitive forearm rotational activities. It has been es-
timated that only 5-10% of cases occur in tennis players
[13]. In our series, 52% cases were manual workers most of
them mechanics, 24% were homemakers mostly females
and rest 24% were involved in sedentary life style with
teachers constituting a substantial 8%.
The optimal treatment strategy for lateral elbow
tendinopathy has baffled treating doctors for long. A large
percentage of cases (70-80%) report resolution of their
symptoms within a year with or without treatment [4].
Conservative line of management is usually the first line
of treatment and consists of activity modification, rest,
RICE (Rest, Ice, compression, elevation) therapy and non
steroidal anti-inflammatory drugs [14]. Manipulation
under anesthesia has been reported to yield good results
[15]. Local corticosteroid injection is one of the
commonest treatment prescribed in cases where initial ac-
tivity modification and NSAIDs don’t work. However, a
randomised control trial conducted by Bisset et al. [16]
found out that corticosteroid although effective at short
term yielded poorer results at long term follow up (1 year)
than physiotherapy.
Several nonsurgical modalities of treatment are under
investigation which upon preliminary research have
reported to provide some relief in symptoms of tennis
elbow. Plazcek et al. [17] investigated the role of Botu-
linum A toxin injection and found out that it offered sig-
nificant pain relief. They reported significant weaknessin the extensor movement of third finger but none of
the patients lost time from work due to this weakness.
D’Vaz [18] conducted a double blinded randomised con-
trolled trial and concluded that pulsed low intensity
ultrasound therapy offered no significant benefit over
placebo.
Recent reports have emerged suggesting a beneficial
role of growth factors delivered locally at the site of
tendinopathy. This can be accomplished by injection of
autologous blood or platelet concentrates. Mishra and
colleagues [19] conducted a study wherein they treated
patients of lateral elbow tendinopathy of less than 6
weeks duration by local injection of platelet rich plasma.
They reported a significant improvement in pain. Simi-
larly Edwards et al. [5] reported dramatic relief in symp-
toms in 28 patients of tennis elbow after injection of
autologous blood. They postulated that autologous blood
initiated an inflammatory reaction which allowed healing
in otherwise degenerative process. Although this study
didn’t involve any control group, the authors hypothe-
sized that blood injection would provide additional ben-
efits over an injection of either saline or steroid. This
Table 5 Between-group comparison of Mean Nirschl
stage at baseline and after 2 and 6 weeks of treatment
Pre injection At 2 weeks At 6 weeks
Group I 4.84 (0.94) 3.20 (0.91) 2.40 (1.15)
Group II 4.52 (1.23) 3.48 (1.39) 1.40 (1.22)
P value # 0.3065 0.436 0.0045
Significance NS NS HS
#unpaired t test, NS – not significant, HS – highly significant.
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tions provided relief to patients who had failed multiple
steroid injection attempts despite similar injection tech-
niques and volumes. A systematic review done by Vos
et al. [20] however found that autologous blood has lim-
ited application in the management of tendinopathy.
This was concluded on the basis of three studies [21-23]
which involved management of plantar fasciitis with in-
jection of autologous blood. The desired results may
have not been achieved since the mechanical and healing
properties of weight bearing and non weight bearing ten-
dons differ a lot.
In our study, comparison between the two groups
showed that both pain values and stage of the disease
were similar at 2 weeks of review but there was a signifi-
cant difference in both values at 6 weeks of follow up.
Statistical analysis concluded that autologous blood was
better than local corticosteroid injection in short term
follow up of tennis elbow patients. This result came in
direct consistency with study of Edwards et al. [5] who
reported maximal pain relief 3 weeks after injection of
autologous blood (clinically pain relief was better at 2
weeks in steroid group in our study). Kazemi et al. [24]
also reported in their trial, that the benefits afforded by
autologous blood injection outweighed those by local
corticosteroid injection.
The mechanism of action of both autologous blood and
platelet rich plasma is attributed to degranulation of α
granules of platelets releasing growth factors which play a
role in tissue healing and regeneration. Platelet derived
growth factor, transforming growth factor β, vascularFigure 2 Line diagram depicting the mean Nirschl stage in pre-injecti
the groups.derived endothelial growth factor, epithelial growth factor,
hepatocyte growth factor and insulin like growth factor
are some of the factors involved [25]. Platelet rich plasma
(PRP) varies in the relative concentration of platelets ran-
ging from 2.5 to 5 times as compared to blood. PRP logic-
ally appears to be more effective than due to higher
concentration of growth factors per unit volume and has
been proved in one clinical trial to be better than autolo-
gous blood. However preparation of platelet concentrates
requires specialised equipment which is both expensive
and time consuming. Autologous blood has a far easier
and prompt application than PRP.
The mechanism of action of steroid remains obscure.
Balasubramaniam et al. [27] theorized that the beneficial
effects of steroid injection result from the bleeding
caused by forcing fluid through tissue planes at high
pressures. In a study by Wolf et al. [28] corticosteroid,
autologous blood and saline injection all afforded the
same benefit in cases of tennis elbow. This indirectly
points out that these reported outcomes may also be
due to the placebo effect of injection itself or a reflectionon phase, at 2 weeks and 6 weeks post-injection in both
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might be led to believe that the disparity in the efficacy
of autologous blood and corticosteroid observed in some
series is due to the relative difference in the quantity of
growth factors delivered to the degenerated tendon.
However this doesn’t explain the fact that maximal relief
encountered by both modalities peaks at different times.
We acknowledge that the major limitation of our study
is a shorter follow up. Long term follow up study is re-
quired to test the ability of blood injection to maintain its
analgesic effect for a longer time. However at longer fol-
low up the contribution of treatment to relief begins to di-
lute as the natural tendency of the disease to heal starts
manifesting in the form of pain relief. Further studies are
required to optimise the number and spacing of injections
for obtaining desired results. Short duration of symptoms
in our series might be perceived as a potential limitation
but since the threshold for steroid injection in tennis
elbow is low, many of the patients with a longer duration
of symptoms had invariably been treated with a steroid in-
jection elsewhere and thus couldn’t be included in the
study. As a corollary, since we enrolled only those patients
which were previously untreated, further studies are
needed to detect any difference in efficacy of blood injec-
tion in cases earlier treated with other modalities. Further
research can also be directed at elucidating the exact
mechanism of action of blood and steroid, which can be
known only by indirect methods in human subjects.
Conclusion
Local injection of autologous blood offers a significant
benefit over single steroid injection in the short term re-
view in the treatment of patients of lateral elbow
tendinopathy.
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